DE07006112T1 - Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor - Google Patents
Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor Download PDFInfo
- Publication number
- DE07006112T1 DE07006112T1 DE07006112T DE07006112T DE07006112T1 DE 07006112 T1 DE07006112 T1 DE 07006112T1 DE 07006112 T DE07006112 T DE 07006112T DE 07006112 T DE07006112 T DE 07006112T DE 07006112 T1 DE07006112 T1 DE 07006112T1
- Authority
- DE
- Germany
- Prior art keywords
- immunoglobulin molecule
- tnfα
- region
- human
- pathology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
Abstract
Chimäres Immunglobulinmolekül, wobei das Immunglobulinmolekül ausgewählt ist aus einem chimären Antikörper, einer chimären Immunglobulinkette, oder einem Fragment oder einer Region davon, wobei das Immunglobulinmolekül mindestens einen Teil einer konstanten menschlichen Immunglobulinregion und mindestens einen Teil einer nicht-menschlichen variablen Immunglobulinregion umfasst, die eine Spezifität für ein neutralisierendes Epitop des menschlichen Tumornekrosefaktors-α (TNFα) aufweist.
Claims (14)
- Chimäres Immunglobulinmolekül, wobei das Immunglobulinmolekül ausgewählt ist aus einem chimären Antikörper, einer chimären Immunglobulinkette, oder einem Fragment oder einer Region davon, wobei das Immunglobulinmolekül mindestens einen Teil einer konstanten menschlichen Immunglobulinregion und mindestens einen Teil einer nicht-menschlichen variablen Immunglobulinregion umfasst, die eine Spezifität für ein neutralisierendes Epitop des menschlichen Tumornekrosefaktors-α (TNFα) aufweist.
- Chimäres Immunglobulinmolekül gemäß Anspruch 1, aufweisend zwei leichte Ketten und zwei schwere Ketten, wobei jede der Ketten mindestens einen Teil einer konstanten Region und mindestens einen Teil einer variablen Region umfasst, wobei die variable Region eine Spezifität für menschlichen TNFα aufweist, wobei das Immunglobulinmolekül mit hoher Affinität an ein neutralisierendes Epitop des menschlichen TNFα in vivo bindet.
- Chimäres Immunglobulinmolekül gemäß Anspruch 1 oder Anspruch 2, wobei: (a) Binden des Immunglobulinmoleküls an TNFα eine pathologische Aktivität von TNFα hemmt; (b) das Immunglobulinmolekül eine Antigen-Bindungsregion aufweist, die an die Reste 87 bis 108 oder sowohl 59 bis 80 als auch 87 bis 108 von hTNFα der SEQ ID NO: 1 bindet; und/oder (c) das Immunglobulinmolekül nicht an ein oder mehrere Epitope bindet, die in den Aminosäuren 11 bis 13, 37 bis 41, 49 bis 57 oder 155 bis 157 von hTNFα mit der SEQ ID NO: 1 eingeschlossen sind.
- Chimäres Immunglobulinmolekül gemäß Anspruch 1, wobei die Immunglobulinkette eine schwere Kette oder eine leichte Kette ist.
- Chimäres Immunglobulinmolekül gemäß Anspruch 1 oder Anspruch 2, wobei die variable Region murinen Ursprungs ist, und gegebenenfalls wobei die variable Region abgeleitet ist von einem murinen monoklonalen Antikörper hoher Affinität, der an ein neutralisierendes Epitop des humanen TNFα bindet, und ferner gegebenenfalls wobei der murine monoklonale Antikörper kompetitiv die Bindung von A2 oder cA2 an TNFα hemmt; und/oder der murine monoklonale Antikörper A2 ist.
- Chimäres Immunglobulinmolekül gemäß Anspruch 2 oder 5, wobei: (a) die Affinität, gemessen als eine Assoziationskonstante (Ka), mindestens 1 × 108 Liter/Mol, zum Beispiel mindestens 1 × 109 Liter/Mol beträgt; und/oder (b) welches humanes TNFα mit einer ID50 von mindestens etwa 1 μg/ml, zum Beispiel mindestens etwa 100 ng/ml, zum Beispiel mindestens etwa 15 ng/ml neutralisiert.
- Ein isoliertes TNF-Polynukleotid, aufweisend eine Nukleotidsequenz, die ein chimäres Immunglobulinmolekül gemäß einem der vorstehenden Ansprüche kodiert, wobei die Nukleotidsequenz mindestens eine variable Region in zweckorientierter Verknüpfung mit mindestens einer konstanten Region kodiert.
- Polynukleotid gemäß Anspruch 7, wobei: (a) die Nukleotidsequenz ausgewählt ist aus einer genomischen DNA-Sequenz oder einer cDNA-Sequenz und/oder (b) das Polynukleotid ein Expressionsvehikel ist.
- Ein Wirt, der mit dem Polynukleotid gemäß Anspruch 7 oder Anspruch 8 transformiert oder transfiziert ist, wobei der Wirt zum Beispiel eine eukaryotische Zelle (zum Beispiel eine Säugerzelle) oder eine Bakterienzelle ist.
- Ein Verfahren zur Herstellung eines chimären Immunglobulinmoleküls gemäß Anspruch 2, aufweisend die Schritte: (a) Kultivieren eines Wirts gemäß Anspruch 9 derart, dass das Immunglobulinmolekül in gewinnbaren Mengen exprimiert wird; und (b) Gewinnen des Immunglobulinmoleküls aus dem Wirt oder der Kultur.
- Eine pharmazeutische Zusammensetzung, aufweisend ein Immunglobulinmolekül gemäß einem der Ansprüche 1 bis 6 oder einen pharmazeutisch verträglichen Ester, Ether, Sulfat, Carbonat, Gluceronid oder Salz hiervon, und einen pharmazeutisch verträglichen Träger.
- Die pharmazeutische Zusammensetzung gemäß Anspruch 11 zur Verwendung bei der Therapie, zum Beispiel bei einem Verfahren zur Behandlung eines Individuums mit einer TNFα-vermittelten Pathologie; und gegebenenfalls wobei die Pathologie ausgewählt ist aus Sepsissyndrom, Kachexie, Kreislaufkollaps und Schock aufgrund von akuter oder chronischer bakterieller Infektion, einer bakteriellen Infektion, einer viralen Infektion, einer Pilzinfektion, systemischem Lupuserythematosus, rheumatoider Arthritis, alkoholbedingter Hepatitis, einer chronisch-entzündlichen Pathologie, einer entzündlichen Gefäßpathologie, einer Transplantat-gegen-Empfänger-Pathologie, Kaisaki-Pathologie und einer malignen Pathologie.
- Ein hoch-affiner monoklonaler Antikörper aus Maus gegen menschlichen Tumornekrosefaktor-α (TNFα), wobei der monoklonale Antikörper (a) kompetitiv die Bindung des Antikörpers A2 an TNF hemmt und (b) an ein neutralisierendes Epitop des humanen TNFα bindet.
- Monoklonaler Antikörper gemäß Anspruch 13, wobei: (a) der Antikörper eine Antigen-Bindungsregion aufweist, die an die Reste 87 bis 108 oder sowohl 59 bis 80 als auch 87 bis 108 von hTNFα der SEQ ID NO: 1 bindet; und/oder (b) der Antikörper, das Fragment oder die Region nicht an ein oder mehrere Epitope bindet, die in den Aminosäuren 11 bis 13, 37 bis 42, 49 bis 57 oder 155 bis 157 von hTNFα mit der SEQ ID NO: 1 eingeschlossen sind.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67082791A | 1991-03-18 | 1991-03-18 | |
US670827 | 1991-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE07006112T1 true DE07006112T1 (de) | 2010-01-21 |
Family
ID=24692048
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE07012626T Pending DE07012626T1 (de) | 1991-03-18 | 1992-03-18 | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
DE07006112T Pending DE07006112T1 (de) | 1991-03-18 | 1992-03-18 | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
DE69231828T Expired - Lifetime DE69231828T3 (de) | 1991-03-18 | 1992-03-18 | Spezifisch gegen menschlichen Tumornekrosefaktor gerichtete monoklonale und chimäre Antikörper |
DE2001199067 Active DE10199067I2 (de) | 1991-03-18 | 1992-03-18 | Fuer Menschlichen Tumornekrose-Faktor spezifische Monoklonale und Chimaere Antikoerper |
DE69233701T Expired - Lifetime DE69233701T2 (de) | 1991-03-18 | 1992-03-18 | Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor |
DE06001779T Pending DE06001779T1 (de) | 1991-03-18 | 1992-03-18 | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
DE07012625T Pending DE07012625T1 (de) | 1991-03-18 | 1992-03-18 | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE07012626T Pending DE07012626T1 (de) | 1991-03-18 | 1992-03-18 | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69231828T Expired - Lifetime DE69231828T3 (de) | 1991-03-18 | 1992-03-18 | Spezifisch gegen menschlichen Tumornekrosefaktor gerichtete monoklonale und chimäre Antikörper |
DE2001199067 Active DE10199067I2 (de) | 1991-03-18 | 1992-03-18 | Fuer Menschlichen Tumornekrose-Faktor spezifische Monoklonale und Chimaere Antikoerper |
DE69233701T Expired - Lifetime DE69233701T2 (de) | 1991-03-18 | 1992-03-18 | Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor |
DE06001779T Pending DE06001779T1 (de) | 1991-03-18 | 1992-03-18 | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
DE07012625T Pending DE07012625T1 (de) | 1991-03-18 | 1992-03-18 | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
Country Status (13)
Country | Link |
---|---|
EP (6) | EP1905782A1 (de) |
JP (8) | JPH06506120A (de) |
AT (2) | ATE366316T1 (de) |
AU (1) | AU668864B2 (de) |
CA (2) | CA2736076A1 (de) |
DE (7) | DE07012626T1 (de) |
DK (2) | DK0610201T4 (de) |
ES (2) | ES2289997T3 (de) |
GR (1) | GR3036375T3 (de) |
HK (1) | HK1037923A1 (de) |
LU (1) | LU90854I2 (de) |
NL (1) | NL300069I2 (de) |
WO (1) | WO1992016553A1 (de) |
Families Citing this family (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
DE07012626T1 (de) | 1991-03-18 | 2010-01-21 | New York University | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
IT1254315B (it) * | 1992-03-27 | 1995-09-14 | Mini Ricerca Scient Tecnolog | Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf. |
DE69321909T2 (de) * | 1992-08-28 | 1999-04-01 | Bayer Ag | Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
US6863890B1 (en) | 1993-02-26 | 2005-03-08 | Advanced Biotherapy, Inc. | Treatment of AIDS with antibodies to gamma interferon, alpha interferon and TNF-alpha |
US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
RU2139092C1 (ru) * | 1993-06-03 | 1999-10-10 | Терапьютик Антибодиз Инк. | Фрагменты антител в терапии |
CA2097952C (en) * | 1993-06-08 | 2006-03-14 | Alex D. Romaschin | Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence |
NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
US5804370A (en) * | 1994-06-08 | 1998-09-08 | Critichem Medical Products Limited | Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence |
US6203997B1 (en) | 1994-06-08 | 2001-03-20 | Sepsis, Inc. | Quantitation of analytes in whole blood |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US20140212413A1 (en) * | 1995-12-11 | 2014-07-31 | New York University | Methods of Treating TNF-alpha-Mediated Diseases Using Chimeric TNF-alpha Antibodies |
HU230048B1 (hu) | 1996-02-09 | 2015-06-29 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazása |
US7608262B2 (en) * | 1996-02-16 | 2009-10-27 | The Kennedy Institute Of Rheumatology | Methods of preventing or treating thrombosis with tumor necrosis factor antagonists |
AU4413097A (en) * | 1996-09-19 | 1998-04-14 | Centocor Inc. | Hiv-1 therapy with il-2 and anti-tnf antibody |
ATE256476T1 (de) * | 1996-11-15 | 2004-01-15 | Kennedy Inst Of Rheumatology | Unterdrückung von tnfalpha und il-12 in der therapie |
JP2001512480A (ja) * | 1997-02-19 | 2001-08-21 | セントコア,インコーポレイテッド | 持続的薬物送達およびそれに有用な組成物 |
EP1170017A1 (de) * | 1997-05-12 | 2002-01-09 | The Kennedy Institute Of Rheumatology | Verwendung des Alpha-Tumornekrosefaktors (TNF-alpha) und des Wachstumsfaktors der vaskularen Endothelzellen (VEGF) zur Herstellung einer therapeutischen Zusammensetzung |
US6159683A (en) * | 1997-12-16 | 2000-12-12 | Spectral Diagnostics, Inc. | Method of determining stage of sepsis |
EP1022027A1 (de) * | 1999-01-22 | 2000-07-26 | Applied Research Systems ARS Holding N.V. | Antagonisten von Tumornecrosefaktor und ihre Verwendungen gegen Endometriose |
ATE488250T1 (de) * | 1999-03-02 | 2010-12-15 | Centocor Inc | Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
JP4812921B2 (ja) * | 2000-04-14 | 2011-11-09 | 田辺三菱製薬株式会社 | ベーチェット病治療剤 |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
EP1379275A4 (de) * | 2001-03-14 | 2005-12-21 | Centocor Inc | Mit chronisch-obstruktiver lungenkrankheit im zusammenhang stehende, von immunglobulin abgeleitete proteine, zusammensetzungen, verfahren und verwendungen |
CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
CN1585778A (zh) * | 2001-11-12 | 2005-02-23 | 默克专利有限公司 | 修饰的抗-TNFα抗体 |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20040126372A1 (en) * | 2002-07-19 | 2004-07-01 | Abbott Biotechnology Ltd. | Treatment of TNFalpha related disorders |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
ES2347239T3 (es) | 2002-12-02 | 2010-10-27 | Amgen Fremont Inc. | Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos. |
US7553827B2 (en) | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US7344716B2 (en) | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US8273347B2 (en) | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
US7429378B2 (en) | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US8361467B2 (en) | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
WO2005082377A1 (ja) | 2004-03-01 | 2005-09-09 | Ajinomoto Co., Inc. | 抗ヒトTNF-α抗体活性低下抑制剤 |
BRPI0508286B8 (pt) | 2004-03-31 | 2021-05-25 | Dana Farber Cancer Inst Inc | método para determinar a probabilidade de eficácia de um inibidor da tirosina quinase egfr para tratar câncer, uso de um inibidor da tirosina quinase de egfr, sonda, kit, e, par de iniciadores |
TWI556829B (zh) | 2004-04-09 | 2016-11-11 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
NZ591701A (en) | 2005-05-16 | 2012-11-30 | Abbott Biotech Ltd | Use of tnf inhibitor for treatment of erosive polyarthritis |
DK1919951T3 (en) * | 2005-08-04 | 2015-02-16 | Janssen Biotech Inc | Anti-tnf-alpha antibodies and methods of use |
JP4861019B2 (ja) * | 2006-01-31 | 2012-01-25 | 独立行政法人科学技術振興機構 | ヒトTNF−αに対する抗体酵素およびその利用 |
TWI392684B (zh) | 2006-04-05 | 2013-04-11 | Abbott Biotech Ltd | 抗體之純化 |
US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
MY161866A (en) | 2006-09-13 | 2017-05-15 | Abbvie Inc | Cell culture improvements |
KR101563753B1 (ko) | 2007-05-11 | 2015-10-27 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 피부 궤양의 치료 방법 |
JP5277243B2 (ja) | 2007-05-11 | 2013-08-28 | トーマス・ジェファーソン・ユニバーシティ | 神経変性疾患および障害を治療および阻止する方法 |
EP2171451A4 (de) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | Verfahren zur behandlung juveniler idiopathischer arthritis |
CN101802005B (zh) | 2007-08-28 | 2015-09-16 | 艾伯维生物技术有限公司 | 包括关于阿达木单抗的结合蛋白质的组合物和方法 |
US8986696B2 (en) | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
JP6078217B2 (ja) | 2008-01-15 | 2017-02-08 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 粉末化されたタンパク質組成物及びその作製方法 |
CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
CN102036683A (zh) * | 2008-05-20 | 2011-04-27 | 株式会社钟化 | 细胞毒性组合物 |
US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
EP3002299A1 (de) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual-variable- domain-immunglobuline und ihre verwendungen |
RU2015105591A (ru) | 2008-06-10 | 2015-08-10 | Эббви Инк. | Новые трициклические соединения |
KR20110031369A (ko) | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | 프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도 |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
JP2009102390A (ja) * | 2009-01-21 | 2009-05-14 | Mitsubishi Tanabe Pharma Corp | ベーチェット病治療剤 |
EP2228652A1 (de) | 2009-03-11 | 2010-09-15 | Medizinische Universität Wien | Verbesserung bei der Tumorbehandlung |
WO2011015916A2 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | Vectors and compounds for expression of recombinant infliximab |
PE20121647A1 (es) | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
CN102666875A (zh) | 2009-10-15 | 2012-09-12 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
SG181147A1 (en) | 2009-12-01 | 2012-07-30 | Abbott Lab | Novel tricyclic compounds |
DK2506716T3 (en) | 2009-12-01 | 2017-09-04 | Abbvie Inc | HIS UNKNOWN TRICYCLIC RELATIONS |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
CL2010000019A1 (es) * | 2010-01-11 | 2010-06-11 | Univ Chile | Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion. |
CA2787783A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
JP5947727B2 (ja) | 2010-01-20 | 2016-07-06 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗ilt5抗体およびilt5結合抗体断片による免疫調節 |
RU2605928C2 (ru) | 2010-03-02 | 2016-12-27 | Эббви Инк. | Терапевтические dll4-связывающие белки |
CN105056232A (zh) | 2010-06-03 | 2015-11-18 | 阿布维生物技术有限公司 | 用于治疗化脓性汗腺炎(hs)的用途和组合物 |
BR112013002578A2 (pt) | 2010-08-03 | 2019-05-14 | Abbvie Inc. | imunoglobinas de domínio variável duplo e usos das mesmas |
EP2600901B1 (de) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung |
AU2011293253B2 (en) | 2010-08-26 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN104531671A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
CN102675460B (zh) | 2011-02-28 | 2015-08-19 | 珠海市丽珠单抗生物技术有限公司 | 抗肿瘤坏死因子α的人源化抗体 |
US8658171B2 (en) | 2011-02-28 | 2014-02-25 | Livzon Mabpharm Inc. | Humanized anti-TNFα antibodies |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
JP6081995B2 (ja) | 2011-06-17 | 2017-02-15 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 癌の処置における治療抗体の標的としてのFrizzled2 |
WO2013003697A1 (en) | 2011-06-30 | 2013-01-03 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
CN103917555A (zh) * | 2011-08-01 | 2014-07-09 | 艾瓦夏生物制剂公司 | 人tnf特异性的牛科动物多克隆抗体 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (de) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
US9573996B2 (en) | 2011-12-16 | 2017-02-21 | Synthon Biopharmaceuticals B.V. | Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases |
TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對il-13及/或il-17之雙特異性結合蛋白 |
JP2012092147A (ja) * | 2012-02-07 | 2012-05-17 | Mitsubishi Tanabe Pharma Corp | ベーチェット病治療剤 |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243953A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
US9206390B2 (en) | 2012-09-02 | 2015-12-08 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
MY194330A (en) | 2012-11-01 | 2022-11-28 | Abbvie Inc | Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof |
DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
WO2014143205A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
WO2014149935A1 (en) * | 2013-03-15 | 2014-09-25 | Janssen Biotech, Inc. | Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CA2918194C (en) | 2013-03-27 | 2022-12-06 | The General Hospital Corporation | Methods and agents for treating alzheimer's disease |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP3052640A2 (de) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
JP5797728B2 (ja) * | 2013-12-20 | 2015-10-21 | 田辺三菱製薬株式会社 | ベーチェット病治療剤 |
SI3116891T1 (sl) | 2014-03-10 | 2020-07-31 | Richter Gedeon Nyrt. | Čiščenje imunoglobulina z uporabo predčistilnih stopenj |
EP3194581A4 (de) | 2014-09-15 | 2018-04-25 | Children's Medical Center Corporation | Verfahren und zusammensetzungen zur erhöhung der somatischen zellkerntransfer(scnt)-effizienz durch entfernung der histon h3-lysin-trimethylierung |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
EP3078675A1 (de) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
HU231463B1 (hu) | 2015-08-04 | 2024-01-28 | Richter Gedeon Nyrt. | Módszer rekombináns proteinek galaktóz tartalmának növelésére |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
EP4219503A1 (de) | 2015-10-16 | 2023-08-02 | AbbVie Inc. | Kristallines l-maleat von (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a!pyrrolo[2,3-e!pyrazin-8-yl)-n-(2,2,2-trifluorethyl)pyrrolidin-1-carboxamid |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
AU2018207367B2 (en) | 2017-01-11 | 2024-02-15 | Celltrion Inc. | Stable Liquid Formula |
EP3573658A4 (de) | 2017-01-30 | 2021-07-21 | Janssen Biotech, Inc. | Anti-tnf-antikörper, zusammensetzungen und verfahren zur behandlung von aktiver psoriatischer arthritis |
WO2018147915A1 (en) | 2017-02-07 | 2018-08-16 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
JP2022502350A (ja) | 2018-08-29 | 2022-01-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 関節リウマチを有する対象を治療するための方法および組成物 |
HUP1800376A2 (hu) | 2018-11-07 | 2020-05-28 | Richter Gedeon Nyrt | Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer |
CN114206442A (zh) | 2019-01-31 | 2022-03-18 | 赛诺菲生物技术公司 | 用于治疗幼年特发性关节炎的抗il-6受体抗体 |
HU231498B1 (en) | 2019-04-04 | 2024-05-28 | Richter Gedeon Nyrt | Improvement of affinity chromatography of immunoglobulins by using pre-capture flocculation |
AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
WO2022123293A1 (ko) | 2020-12-09 | 2022-06-16 | 에이치케이이노엔 주식회사 | 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도 |
WO2024054934A1 (en) | 2022-09-07 | 2024-03-14 | Mdx Management Llc | Shp-1 inhibitors for treating cancer |
WO2024097804A1 (en) | 2022-11-02 | 2024-05-10 | Mdx Management Llc | Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3631229A1 (de) * | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
EP0288088B1 (de) * | 1987-04-24 | 1994-03-09 | Teijin Limited | Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung |
DE3823804A1 (de) * | 1988-07-14 | 1990-01-18 | Basf Ag | Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten |
AU626572B2 (en) * | 1988-07-18 | 1992-08-06 | Chiron Corporation | Monoclonal antibodies reactive with cachectin |
PT92900A (pt) * | 1989-01-24 | 1990-07-31 | Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos | |
DK0486526T3 (da) * | 1989-08-07 | 1996-06-24 | Peptide Technology Ltd | Bindingsligander for tumornekrosefaktor |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE07012626T1 (de) | 1991-03-18 | 2010-01-21 | New York University | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
-
1992
- 1992-03-18 DE DE07012626T patent/DE07012626T1/de active Pending
- 1992-03-18 AT AT00204461T patent/ATE366316T1/de active
- 1992-03-18 AU AU17649/92A patent/AU668864B2/en not_active Expired
- 1992-03-18 DE DE07006112T patent/DE07006112T1/de active Pending
- 1992-03-18 DK DK92910625T patent/DK0610201T4/da active
- 1992-03-18 DK DK00204461T patent/DK1097945T3/da active
- 1992-03-18 CA CA2736076A patent/CA2736076A1/en not_active Expired - Lifetime
- 1992-03-18 WO PCT/US1992/002190 patent/WO1992016553A1/en active IP Right Grant
- 1992-03-18 DE DE69231828T patent/DE69231828T3/de not_active Expired - Lifetime
- 1992-03-18 DE DE2001199067 patent/DE10199067I2/de active Active
- 1992-03-18 EP EP07012625A patent/EP1905782A1/de not_active Withdrawn
- 1992-03-18 JP JP4509686A patent/JPH06506120A/ja not_active Withdrawn
- 1992-03-18 ES ES00204461T patent/ES2289997T3/es not_active Expired - Lifetime
- 1992-03-18 EP EP07006112A patent/EP1857553A1/de not_active Withdrawn
- 1992-03-18 DE DE69233701T patent/DE69233701T2/de not_active Expired - Lifetime
- 1992-03-18 EP EP06001779A patent/EP1681305A3/de not_active Withdrawn
- 1992-03-18 EP EP92910625A patent/EP0610201B2/de not_active Expired - Lifetime
- 1992-03-18 ES ES92910625T patent/ES2156859T5/es not_active Expired - Lifetime
- 1992-03-18 EP EP07012626A patent/EP1857554A1/de not_active Withdrawn
- 1992-03-18 DE DE06001779T patent/DE06001779T1/de active Pending
- 1992-03-18 DE DE07012625T patent/DE07012625T1/de active Pending
- 1992-03-18 AT AT92910625T patent/ATE201234T1/de active
- 1992-03-18 EP EP00204461A patent/EP1097945B1/de not_active Expired - Lifetime
- 1992-03-18 CA CA002106299A patent/CA2106299C/en not_active Expired - Lifetime
-
2001
- 2001-08-10 GR GR20010401231T patent/GR3036375T3/el unknown
- 2001-11-09 HK HK01107917A patent/HK1037923A1/xx not_active IP Right Cessation
- 2001-11-13 LU LU90854C patent/LU90854I2/fr unknown
- 2001-11-14 NL NL300069C patent/NL300069I2/nl unknown
-
2003
- 2003-12-10 JP JP2003436484A patent/JP2004180686A/ja active Pending
-
2007
- 2007-04-12 JP JP2007105234A patent/JP2007254477A/ja not_active Withdrawn
- 2007-04-12 JP JP2007105224A patent/JP2007197457A/ja not_active Withdrawn
-
2008
- 2008-03-11 JP JP2008061505A patent/JP2008195724A/ja not_active Withdrawn
- 2008-03-11 JP JP2008061497A patent/JP2008156371A/ja not_active Withdrawn
-
2011
- 2011-05-25 JP JP2011117072A patent/JP2011155992A/ja not_active Withdrawn
-
2012
- 2012-01-12 JP JP2012004156A patent/JP2012087144A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE07006112T1 (de) | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor | |
DE69920897T2 (de) | Monoklonale antikörper mit verringerter immunisierungsfähigkeit | |
DE60124863T2 (de) | Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper | |
US4978745A (en) | Immunoreactive heterochain antibodies | |
DE69532889T2 (de) | Interleukin-5-spezifische rekombinante antikörper | |
EP0388964B1 (de) | Verfahren zur Herstellung hetero-bispezifischer Antikörper | |
DE69637148T2 (de) | Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen | |
AU690557B2 (en) | New therapeutic, anti-proteic mediator kits, a process for their preparation and pharmaceutical compositions containingthem | |
DE14172437T1 (de) | Herstellungsverfahren eines Antikörpers bestehend aus einer menschlichen variablen Region und einer konstanten Region eines Nagetiers | |
DE69434223T2 (de) | In der Behandlung von IL4 auslösenden Krankheiten nützliche rekombinante IL4-Antikörper | |
DE98204240T1 (de) | Verfahren zur Herstellung humanisierter Immunglobuline | |
CA2165573A1 (en) | Anti-.alpha.v-integrin monoclonal antibody | |
IL93118A0 (en) | Expression vectors,cells transformed thereby and their use in the production of chimeric monoclonal antibodies | |
EP1888642B1 (de) | Bindungspartner des plazentalen wachstumsfaktors insbesondere gegen den plazentalen wachstumsfaktor gerichtete antikörper, ihre herstellung und verwendung | |
EP0531300A1 (de) | Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie. | |
WO2022031871A4 (en) | Compositions and methods related to il27 receptor binding | |
RU96109042A (ru) | Рекомбинантные il4 антитела, используемые для лечения нарушений, связанных с действием il4 | |
DE69435083T2 (de) | Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen | |
CA2132540A1 (en) | A monoclonal antibody to a human mdr1 multidrug resistance gene product, and uses | |
DE19718249A1 (de) | Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung | |
DE100955T1 (de) | Monoklonale immunoglobulin-m-antikoerper und verfahren zu deren herstellung. | |
EP0262571B1 (de) | Neue monoklonale Antikörper gegen IFN-omega, Verfahren zu ihrer Herstellung und deren Verwendung zur Reinigung sowie zum Nachweis von IFN-omega | |
Kardost et al. | Generation and characterization of three murine monoclonal nucleotide binding anti-ssDNA autoantibodies | |
French et al. | The molecular and biochemical characterization of mutant monoclonal antibodies with increased antigen binding. | |
DE69434731T2 (de) | Ein Gen das für ein Polypeptid kodiert welches die Fähigkeit hat Prä-B Zellwachstum zu ermöglichen |